Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Navicare Biotech Co's enterprise value is NT$1,572.1 Mil.
Navicare Biotech Co's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was NT$21.0 Mil. Therefore, Navicare Biotech Co's EV-to-EBITDA for today is 74.75.
The historical rank and industry rank for Navicare Biotech Co's EV-to-EBITDA or its related term are showing as below:
ROCO:8472'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -88.13 Med: -5.77 Max: 426.62
Current: 74.75
During the past 13 years, the highest EV-to-EBITDA of Navicare Biotech Co was 426.62. The lowest was -88.13. And the median was -5.77.
ROCO:8472's EV-to-EBITDA is ranked worse than 94.58% of 959
companies
in the Retail - Cyclical industry
Industry Median: 8.65
vs ROCO:8472: 74.75
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Navicare Biotech Co (ROCO:8472) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Navicare Biotech Co's PE Ratio (TTM) for today is calculated as:
Navicare Biotech Co's share price for today is NT$80.00.
Navicare Biotech Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$-0.640.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Navicare Biotech Co's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:8472 vs AMZN, BABA, PDD: EV-to-EBITDA Comparison
For the Internet Retail subindustry, Navicare Biotech Co's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Navicare Biotech Co EV-to-EBITDA vs Retail - Cyclical Industry
For the Retail - Cyclical industry and Consumer Cyclical sector, Navicare Biotech Co's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Navicare Biotech Co's EV-to-EBITDA falls into.
Navicare Biotech Co's current Enterprise Value is NT$1,572.1 Mil.
Navicare Biotech Co's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$21.0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Navicare Biotech Co (ROCO:8472) has a EV-to-EBITDA of 74.75 as of Sep. 12, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Navicare Biotech Co. According to the industry distribution chart, Navicare Biotech Co ranks #907 out of 959 companies in the Retail - Cyclical industry, placing it in the top 94.6%.
Is Navicare Biotech Co's EV-to-EBITDA too high?
Navicare Biotech Co's current EV-to-EBITDA is 74.75. The Retail - Cyclical industry median EV-to-EBITDA is 8.65. Navicare Biotech Co's value of 74.75 is 764.2% above this industry median. Based on the distribution chart, Navicare Biotech Co ranks #907 out of 959 companies in the Retail - Cyclical industry, which is in the bottom quartile relative to peers. Overall, Navicare Biotech Co has a GF Score™ of 62/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Navicare Biotech Co's EV-to-EBITDA compare to AMZN and BABA?
According to the Retail - Cyclical industry distribution chart, Navicare Biotech Co ranks #907 out of 959 companies for EV-to-EBITDA. This places Navicare Biotech Co in the lower half of its industry. The industry median EV-to-EBITDA is 8.65. Navicare Biotech Co's value of 74.75 is 764.2% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Retail - Cyclical company?
The median EV-to-EBITDA among Retail - Cyclical companies is 8.65, based on 959 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Navicare Biotech Co's current EV-to-EBITDA of 74.75 is 764.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Navicare Biotech Co. For the Retail - Cyclical industry, the median EV-to-EBITDA is 8.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Navicare Biotech Co's current EV-to-EBITDA is 74.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Navicare Biotech Co stock overvalued right now?
Based on GuruFocus' analysis, Navicare Biotech Co (ROCO:8472) is currently considered Significantly Overvalued. The stock's GF Value™ is NT$45.06, compared to a current price of NT$80.00 — trading 77.5% above its estimated fair value. The current EV-to-EBITDA is 74.75 and 764.2% above the Retail - Cyclical industry median of 8.65. Navicare Biotech Co's overall GF Score™ is 62/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Navicare Biotech Co (ROCO:8472), the current EV-to-EBITDA is 74.75 as of Sep. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Navicare Biotech Co (ROCO:8472) Overvalued in 2026?
Based on GuruFocus' analysis, Navicare Biotech Co stock appears to be overvalued.
The current stock price of NT$80.00 is trading 77.5% above its estimated GF Value™ of NT$45.06.
GuruFocus considers Navicare Biotech Co to be Significantly Overvalued.
Key valuation signals for ROCO:8472:
EV-to-EBITDA: 74.75
GF Value™: NT$45.06 vs. price of NT$80.00 (77.5% above fair value)
Industry Position: 764.2% above the Retail - Cyclical median (#907 of 959)
No single metric tells the full story. See the ROCO:8472 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:8472 has been successfully added to your 
